Minimally invasive radiation treatment for wet AMD nears market

Minimally invasive radiation treatment for wet AMD nears market
Howard Larkin
Howard Larkin
Published: Thursday, September 8, 2016
[caption id="attachment_5155" align="alignnone" width="750"]OLYMPUS DIGITAL CAMERA Inserted into the sub-Tenon’s space, the lighted tip of the Salutaris SMD-DA can be seen through an ophthalmoscope, allowing precise positioning of a radioisotope seed under wet AMD lesions Salutaris Medical Devices introduced a new generation of its epsicleral brachytherapy device for treating necovascular age-related macular degeneration at the Ophthalmology Futures European Forum in Copenhagen, Denmark, Thursday. Designed to reduce the need for ongoing anti-VEGF intravitreal injections, the new device is expected to receive the CE Mark by year’s end, said Salutaris CEO Laurence J Marsteller MD. “Our new commercial-ready applicator system is a significant marker of SalutarisMD’s continued progress and we are looking forward to positively affecting patient outcomes,” Dr Marsteller said. The new SMD-DA device treats wet AMD by exposing a target lesion to a strontium-90 radioisotope seed delivering ionizing radiation with anti-angiogenic and anti-inflammatory effects. It consists of a curved cannula with a lighted tip, which is placed directly behind the target lesion. The seed is then advanced from the handle to precisely deliver a prescribed radiation dose. Because it does not penetrate the globe, the 15-minute outpatient procedure is safer than brachytherapy using an epimacular probe, which requires vitrectomy, Dr Marsteller noted. SMD-DA improves dosimetry control over the first-generation SMD-1, increasing chances that the entire target lesion will be treated, Dr Marsteller said. In a test of the earlier device, three of four treatment-naïve patients and one of two chronically treated wet AMD patients saw best corrected visual acuity improve four to 25 letters two years following treatment. Two of the treatment-naïve patients required no further anti-VEGF injections at two years. The new device has received USA regulatory approval for an investigational clinical trial.
Latest Articles
Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

Read more...

New Award to Encourage Research into Sustainable Practices

Read more...

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Read more...

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Read more...

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

Read more...

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

Read more...